Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987681 | 0.86 | KCNJ1 (0.43) | HTTMEN1KMT2AMAPTACHE | |
| SCHEMBL5534441 | 0.82 | DDB1 (0.41) | CASP1CASP7MEN1KMT2AMAPT | |
| SCHEMBL2027366 | 0.81 | GRIN2B (0.38) | GRIN2BALDH1A1 | |
| SCHEMBL1393796 | 0.77 | TDP2 (0.47) | HTTMAPTALDH1A1TDP2 | |
| SCHEMBL1394805 | 0.77 | TDP2 (0.47) | HTTMAPTALDH1A1TDP2 | |
| SCHEMBL380223 | 0.77 | TDP2 (0.47) | HTTMAPTALDH1A1TDP2 | |
| SCHEMBL2024448 | 0.75 | HTR1A (0.43) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1997187 | 0.71 | MAPT (0.50) | GRIN2BRAB9AMEN1KMT2AMAPT | |
| SCHEMBL3596541 | 0.70 | MAPK1 (0.47) | GRIN2BRAB9ACASP1CASP3CASP4 | |
| SCHEMBL30806270 | 0.68 | CASP1 (0.55) | GRIN2BRAB9ACASP1CASP3CASP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071770-B2 | Spirohydantoin aryl CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071771-B2 | Bicyclic spirohydantoin CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1794146-B1 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1951251-B1 | SPIROHYDANTOIN ARYL CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-07-09 | — | — | US | disclosed |
| EP-1608627-B1 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1608627-A4 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1794146-A2 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| US-7202251-B2 | Bicyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2006-09-21 | — | — | US | disclosed |
| WO-2006031676-A2 | TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1608627-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | Merck & Co. Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004082605-A2 | BICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211712-A1 | Bicyclic anilide spirohydantoin cgrp receptor antagonists | BDKRB2, CALCRL, CCKBR | GRIN2B 211/4885RAB9A 1664/4885CASP1 1662/4885 |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | GRIN2B 132/4885RAB9A 2320/4885CASP1 1721/4885 |
| US-20090239870-A1 | Spirohydantoin Aryl Cgrp Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | GRIN2B 196/4885RAB9A 1707/4885CASP1 1512/4885 |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | C1R, CALCB, MRGPRX2 | GRIN2B 61/4885RAB9A 1809/4885CASP1 2573/4885 |
| US-20090176757-A1 | Bicyclic Spirohydantoin CGRP Receptor Antagonists | BDKRB1, BDKRB2, CALCRL | GRIN2B 138/4885RAB9A 1893/4885CASP1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.